Nautilus Biotechnology Inc (NAS:NAUT)

Q4 2024 Nautilus Biotechnology Inc Earnings Call Transcript

Feb 27, 2025 / 01:30 PM GMT

Release Date Price: $1.17 (-18.18%)

Transcript 10-K8-K

Key Points

Positve

Nautilus Biotechnology Inc (NAUT) has made significant progress in developing its proteome analysis platform, with advancements in reagent production, instrument capabilities, and software for data processing.
The company has developed a large number of probes that successfully bind to epitopes spanning the human proteome, demonstrating the potential for broad-scale proteomics applications.
Nautilus Biotechnology Inc (NAUT) has shown promising results in tau proteoform analysis, which could have implications for Alzheimer's disease research and potential partnerships.
The company has maintained flat operating expenses year-over-year, demonstrating effective cost management despite increased R&D and administrative expenses.
Nautilus Biotechnology Inc (NAUT) has a strong cash position with approximately $206 million in cash equivalents and investments, extending its cash runway through 2027.

Negative

The launch of Nautilus Biotechnology Inc (NAUT)'s proteome analysis platform has been delayed to late 2026, impacting the timeline for commercialization.
The company had to reduce its headcount by approximately 16% to align resources with its extended development timeline and cash runway.
Nautilus Biotechnology Inc (NAUT) reported a net loss of $70.8 million for fiscal year 2024, an increase of 11% compared to the previous year.
There are ongoing challenges in optimizing assay configuration and surface chemistry, which have contributed to the delay in platform launch.
The company faces technical risks in achieving high yield and performance from its probe candidates, which are critical for the success of its proteome analysis platform.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NAUT.OQ - Nautilus Biotechnology Inc
Q4 2024 Nautilus Biotechnology Inc Earnings Call
Feb 27, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by.

Welcome to the Nautilus 4th quarter and full year 2024 earnings conference call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Gian E, head of investor relations.

------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.